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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYThe functions of retinoic acid (RA), a potent morphogen with crucial roles in embryogenesis including developmental hematopoiesis,
have not been thoroughly investigated in the human setting. Using an in vitro model of human hematopoietic development, we eval-
uated the effects of RA signaling on the development of blood and on generated hematopoietic progenitors. Decreased RA signaling
increases the generation of cells with a hematopoietic stem cell (HSC)-like phenotype, capable of differentiation into myeloid and
lymphoid lineages, through two separate mechanisms: by increasing the commitment of pluripotent stem cells toward the hematopoi-
etic lineage during the developmental process and by decreasing the differentiation of generated blood progenitors. Our results demon-
strate that controlled low-level RA signaling is a requirement in human blood development, and we propose a new interpretation of RA
as a regulatory factor, where appropriate control of RA signaling enables increased generation of hematopoietic progenitor cells from
pluripotent stem cells in vitro.INTRODUCTION
During embryonic development, retinoic acid (RA) acts as a
morphogen, providing signals that instruct commitment of
unspecified precursors toward separate cell fates, thereby
helping to mediate tissue patterning and organogenesis
(Duester, 2008; Kumar and Duester, 2011; Ross et al.,
2000). As such, RA is also a potent teratogen capable of dis-
turbingdevelopmental processes, causing severemalforma-
tions of the fetus. RA is a signaling molecule derived from
vitaminA (retinol), regulating cellular proliferation and dif-
ferentiation, and is produced by cells that express the en-
zymes retinaldehyde dehydrogenase 1 (RALDH1),
RALDH2, or RALDH3. A small molecule, diethylaminoben-
zaldehyde (DEAB), inhibits the activity of these enzymes
and can be used to limit endogenous RA signaling (Moreb
et al., 2012; Perz-Edwards et al., 2001; Russo and Hilton,
1988). When available, RA enters the nucleus to bind the
retinoic acid receptor (RAR) family of nuclear receptors
that, in turn, by forming heterodimeric complexes with
the retinoid-X-receptor (RXR) family, localize to specific ret-
inoic acid response elements (RAREs) in promoter regions
of the genome to drive transcription of RA target genes.
Modulation of RA in in vitro models of development pro-
vides a useful tool toward understanding commitment
into tissues that depend either on high levels of RA, such
as the developing ectodermal and endodermal derivatives
(Murry and Keller, 2008) or on low levels of RA such as
the posterior patterning of the lateral plate mesodermStem Cell(LPM) (Deimling andDrysdale, 2009).While several model
organisms including Xenopus (Xenopus laevis), zebrafish
(Danio rerio), and mouse (Mus musculus) have been used to
study the effects of RA on embryonic development, similar
studies have not been possible in the human setting for
both technical and ethical reasons. In addition to its role
in embryonic development, RA is also known to have
strong effects on the hematopoietic lineage. However, the
studies on the role of RA in regulating adult hematopoiesis
haveyieldedopposing results. For example, RA signaling in-
hibition expands hematopoietic progenitors in both the
human and murine setting (Chute et al., 2006; Muramoto
et al., 2010), while other studies report increased mainte-
nance and self-renewal upon adding RA to short- and
long-term repopulating hematopoietic stem cells (HSCs)
in the murine setting, mediated through activation of the
RARg receptor (Purton et al., 2000, 2006). These apparent
contradictions likely reflect the increasingly complex na-
ture of RA signaling that is emerging in the field, which is
why amore contextual understandingmight provide a bet-
ter model to explain these previous findings. Indeed, work
analyzing the effects of RA on different subpopulations of
adult blood demonstrated that RA has a pleiotropic effect,
enhancing the self-renewal of the HSC compartment while
accelerating the differentiation of downstream progenitors
(Purton et al., 1999). Several groups have created protocols
that allow in vitro generation of hematopoietic cells from
human pluripotent stem cells (Kardel and Eaves, 2012;
Murry and Keller, 2008; Woods et al., 2011), with moreReports j Vol. 4 j 269–281 j February 10, 2015 j ª2015 The Authors 269
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Figure 1. Retinoic Acid Signaling Inhibition Increases the Yield of Hematopoietic Progenitors with an HSC-like Phenotype from
Human Pluripotent Stem Cells
(A) Schematic of pluripotent stem cell differentiation system used to model human hematopoietic development through mesoderm
specification and blood commitment. RA inhibitors or RA was present continuously during the 16-day differentiation, except where
otherwise stated.
(B) Representative FACS plots showing the hematopoietic population derived from pluripotent stem cells at day 16 of differentiation. FACS
gates show blood (CD45/43+), hematopoietic progenitors (CD45/43+CD34+), and HSC-like immature progenitors (CD45/
43+CD34hiCD38loCD90+CD45RA). Gates are based on FMO controls with more stringent CD34hi and CD38lo gating based on cord blood
hematopoietic stem and progenitor cell standards. Doublet exclusion and dead cell exclusion were done before applying the gates.
(legend continued on next page)
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recent reports demonstrating the generation of definitive
hematopoietic cells capable of differentiation into the
lymphoid lineage (Kennedy et al., 2012; Timmermans
et al., 2009).However, efficient generationofhematopoietic
stem and progenitor cells, with functional properties of
their in vivo counterparts, remains challenging, possibly
due to the current limitations to how accurately the condi-
tions of embryonic blood development can be reproduced
in vitro. In this study, using a human pluripotent stem cell
differentiation system, we model hematopoietic develop-
ment and increase the generation efficiency of hematopoi-
etic cells with an HSC-like phenotype by limiting RA
signaling during directed pluripotent stem differentiation
toward blood. RA signaling inhibitionmaintains immature
progenitors ina lessdifferentiated stateandenables efficient
commitment toward the hematopoietic lineage during
multiple stages of the developmental process. Our results
define the role of RA in hematopoietic differentiation and
provide evidence that low levels of RA signaling promote
hematopoietic development from pluripotent stem cells.RESULTS
Decreased Retinoic Acid Signaling Increases
the Generation of Hematopoietic Progenitors
from Human Pluripotent Stem Cells
Using a 16-day embryonic stem cell (ESC)/induced pluripo-
tent stem cell (iPSC) differentiation system based on our
previously described protocol (Woods et al., 2011) to model
human embryonic development toward the hematopoietic
lineage, we assessed the effects of RA signaling on hemato-
poietic precursor lineage commitment, multilineage differ-
entiation, and proliferation capacities (Figure 1A). We used
established cell-surface markers of hematopoietic progeni-
tors and HSCs and assessed their frequencies in our ESC/
iPSC-derived hematopoietic cells (Figure 1B). The cord
blood-based phenotypic markers were as follows: hemato-
poietic progenitors: CD45+CD34+, multipotent progenitors
(MPPs): CD45+CD34+CD38CD90CD45RA+, and HSCs:
CD45+CD34+CD38CD90+CD45RA (Majeti et al., 2007).
The early pan hematopoietic marker, CD43 (Vodyanik
et al., 2006),was includedtoensure that all ESC/iPSC-derived
blood cells were identified. Early observations such as accel-
erated differentiation of OP9 cells to adipocytes, and the
presence of beating colonies (indicating the presence of car-
diomyocytes) (data not shown) made us consider the possi-(C) Frequency (%) of blood subfractions derived from cells treated with
(see also Figures S1A and S1B) or RA (orange) (0.01, 0.1, 1.0 mM; n = 3
by the dotted line (100%). X = no events. Bar graphs show change in
(D) mRNA expression level of RA target gene RARb at day 8 of differe
(E) Frequency of the HSC-like fraction in cells treated with DEAB (n = 7)
Data represent mean ± SEM. Asterisks indicate significant differences
Stem Cellbility of elevated RA signaling in our cultures with a possible
impact on final blood generation efficiency. Therefore, RA
signaling was evaluated by means of both inhibition using
the RA synthesis inhibitorDEAB andby adding RA. The rela-
tive proportions of viable hematopoietic cells, hematopoiet-
ic progenitors, and HSC-like cells were measured by fluores-
cence-activated cell sorting (FACS) analysis (Figure 1B).
Viability was assessed by 7-aminoactinomycin D (7AAD)
exclusion, andnochange in total viabilitywasobservedafter
applyingDEAB and RA. RA inhibition byDEAB significantly
increased the frequency of HSC-like fraction by 2.3-fold
while showing no significant change in the frequency of to-
tal hematopoietic cells or the more mature progenitor frac-
tion (Figure 1C, left panels). This HSC-like cell increase was
also seen when using the alternative pluripotent human
stem cell lines H1 and HUES33 (Figures S1A and S1B). RA at
the highest concentration of 1 mM, reported as a physiolog-
ical concentration in the developing central nervous system
and retina (Ross et al., 2000), resulted incompleteabrogation
of blood cell production (Figure 1C, upper right panel).
Decreasing doses of RA concentration (0.1 mM and
0.01mM) restored the presence of hematopoietic progenitors
(Figure 1C). However, the frequency of HSC-like cells re-
mained significantlydecreased evenat the lowest concentra-
tion (0.01 mM) (Figure 1C, lower right panel). To verify that
DEAB and RA were indeed modulating RA signaling in our
cultures, we measured the expression level of known RA
target gene RAR-b and observed a significant decrease in
expression with DEAB. At a low concentration of RA, RAR-
b expression was enhanced (Figure 1D). In addition, to
confirm the role of RA signaling inhibition by DEAB in
increasing HSC-like cell frequency, we performed pluripo-
tent stem cell differentiation experiments using the alterna-
tive RA signaling inhibitor LG1506, previously described to
act as an inverse agonist (Safi et al., 2009), and observed an
increase in phenotypic HSCs, similar to DEAB (Figure 1E).
Taken together, these results demonstrate that limiting
retinoic acid signaling during pluripotent stem cell differen-
tiation increases the generation of more primitive hemato-
poietic progenitor cells.Increased Generation of Hematopoietic Progenitors
with Colony-Forming Capacity through Decreased
Retinoic Acid Signaling
To evaluate the effects of RA signaling on the functionality
of blood cells generated from human pluripotent stemDEAB (green) at 10 mM from seven independent experiments (n = 7)
). All values are normalized to the DMSO control (gray) as indicated
cell viability as measured by 7AAD for tested conditions.
ntiation (n = 3).
or an alternative RA signaling inhibitor, LG1506 (1 mM) (blue, n = 3).
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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Figure 2. Retinoic Acid Signaling Inhibition Increases Colony-Forming Hematopoietic Progenitor Numbers
(A) Micrographs of CFU colony types from iPSC-derived cultures (20,000 cells per sample).
(B) Cytospin pictures of various hematopoietic cell types collected from colonies and stained with May Gru¨nwald/Giemsa staining,
alternatively benzidine.
(C) Fold change in CFUs from cells treated with DEAB (green) normalized to DMSO control (gray) indicated by the dotted line (100%) from
seven independent experiments (n = 7), with pie charts showing the distribution of different colony types.
(D) Fold change in CFUs after RA treatment, with pie charts showing colony distribution (n = 3).
(E) Change in maturation markers CD34 and CD38 of the hematopoietic compartment (CD45/43+) of cells treated with or without RA. Arrow
in FACS plot indicates progression of maturing phenotype.
Data represent mean ± SEM. Asterisks indicate significant differences (**p < 0.01, ***p < 0.001).cells, we plated 20,000 bulk cells, harvested at day 16, into
the colony-forming unit (CFU) assay tomeasure the output
in cells capable of forming hematopoietic colonies when
seeded in cytokine containing methylcellulose. Colony
types were identified and scored according to their pheno-
types (Figure 2A). Cytospin analysis confirmed the pres-272 Stem Cell Reports j Vol. 4 j 269–281 j February 10, 2015 j ª2015 The Aence of several types of hematopoietic cells including
macrophages, monoblasts, myeloblasts, neutrophils, and
eosinophils (Figure 2B). RA inhibition by DEAB during
the 16-day differentiation significantly increased the out-
put of CFUs by 2.5-fold as compared to the DMSO control
(Figure 2C, left panel). Compared to the DMSO control,uthors
DEAB-treated cultures had a similar distribution of colony
types including macrophages, granulocytes, mixed col-
onies, and erythroid colonies. DEAB-treated cells occasion-
ally gave rise to colonies containing all lineages (GEMM)
(Figure 2C, right panels). In case of differentiating cells
treatedwith RA, we observed a complete lack of CFU poten-
tial on using 1 mMRA, confirming the block of hematopoi-
etic cell production (Figure 2D, left panel). Lower concen-
trations of RA yielded hematopoietic colonies, with the
lowest concentration at 0.01 mM showing a trend (p =
0.17) for an increase in the frequency of colonies. This is
likely the result of higher numbers of more mature progen-
itors (CD34+CD38+) at the expense of the more immature
progenitor fraction (CD34+CD38) (Figure 2E), indicating
that RA accelerates the maturation of hematopoietic pro-
genitors. Of note, there were no erythroid colonies at any
concentration of RA (Figure 2D, right panel). Together,
these results demonstrate that RA signaling, in a concentra-
tion-dependent manner, decreases the generation effi-
ciency of hematopoietic progenitors with colony-forming
capacity from human pluripotent stem cells and that
reduced RA levels enable a higher generation efficiency of
more immature blood cells.
Retinoic Acid Inhibition Enhances the Lymphoid
and Myeloid Differentiation Capacity of
Hematopoietic Progenitors Generated from Human
Pluripotent Stem Cells
We set out to assess if the observed increase in the imma-
ture progenitor fraction using DEAB, was directly related
to the functional improvements seen with the colony
assay. We analyzed the differentiation capacity of sorted
blood subfractions using a range of different differentiation
protocols. First, we sorted equal numbers of hematopoietic
progenitor cells (CD45/CD43+CD34+) that had been gener-
ated with or without DEAB andmeasured their CFU poten-
tial. We observed that cells generated with DEAB produced
twice the amount of CFUs as compared to the DMSO
control and produced a similar number of CFUs when
compared to similarly sorted cord blood (Figure 3A). We
then evaluated differentiation capacity of hematopoietic
cells toward the lymphoid lineage. We analyzed the
lymphoid commitment of hematopoietic progenitors by
subculture on either the OP9 or the OP9DL1 stroma. By us-
ing OP9 stroma cells for the differentiation toward natural
killer (NK) cells, we could evaluate the capacity of the HSC-
like (CD34+CD38CD90+) fraction as compared to the
matured fraction (CD34+CD38CD90) (Figures 3B and
S2). For reference, sorted cord blood cells were used as pos-
itive control. Of note, cord blood cells generally demon-
strated >100-fold higher proliferative capacity compared
to their in vitro-generated counterparts across these assays
(data not shown). By examining events positive for theStem Cellmarkers of NK cells, we observed that the CD90+ fraction
was superior to the CD90 fraction (Figure 3B, lower left
panel, and Figure S2) indicating that the HSC-like fraction
of cells generated fromhuman pluripotent stem cells repre-
sents the population with a robust capacity to differentiate
toward the lymphoid lineage. For reference, the more
mature CD38+ hematopoietic fraction (of cells generated
in vitro) was evaluated but did not demonstrate any
lymphoid or myeloid differentiation capacity (data not
shown). NK cluster size from cells generated with or
without DEAB showed no significant difference (Figure 3B,
lower left panel); however, given the increase in HSC-like
cells (Figure 1C), the total increase in NK generation from
pluripotent stem cells was estimated to be 3-fold using
DEAB. We then wanted to evaluate the lymphoid capacity
of cells generated in presence of RA. Due to the low fre-
quency of the HSC-like fraction as seen with RA, we evalu-
ated the CD34+ population. By sorting out CD34+ cells,
generated either with or without DEAB or RA, and subcul-
turing them on OP9DL1 for 3 weeks, we observed the pres-
ence of non-myeloid (CD33/CD14) CD7+ and CD45RA+
cells, similar to multipotent early lymphoid progenitors
(Hao et al., 2001; Hoebeke et al., 2007; Larbi et al., 2014)
(Figure 3C).We observed no significant difference in capac-
ity to differentiate into these cells from hematopoietic pro-
genitors generated with or without DEAB or RA, with a
possible explanation due to the beneficial role of RA in
T cell differentiation (Chenery et al., 2013). Together, these
results demonstrate that inhibiting RA signaling with
DEAB during the generation of hematopoietic cells from
human pluripotent stem cells generates cells with the func-
tional capacity to further differentiate toward the
lymphoid and the myeloid lineage.
Retinoic Acid Inhibition Increases the Early
Developmental Commitment toward the
Hematopoietic Lineage
The observation that high-dose RA abrogated blood cell
generation (Figure 1C) suggested that the developmental
commitment toward the hematopoietic lineage might
have been compromised at the level of a non-hematopoiet-
ic upstream precursor. Therefore, we reasoned that, during
this process, RA inhibition by DEAB might have early pos-
itive effects, allowingmore of the initial pluripotent cells to
differentiate into hematopoietic mesoderm prior to blood
production. Indeed DEAB, only during the initial 8 days
of the protocol, established a significant positive effect on
the final frequency of the HSC-like fraction that was less
than the improvement seen when DEAB was applied
throughout the protocol (days 0–16) (Figure 4A). Further-
more, measuring the recently characterized mesodermal
precursor of the definitive hematopoietic lineage character-
ized by a cell-surface marker phenotype highly expressingReports j Vol. 4 j 269–281 j February 10, 2015 j ª2015 The Authors 273
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Figure 3. Retinoic Acid Inhibition Increases the Differentiation Capacity of Hematopoietic Progenitors toward Myeloid and
Lymphoid Lineage
(A) CFU potential of 500 sorted progenitors (CD45/CD43+CD34+) from DEAB-treated cultures (green) and DMSO control (gray) from four
independent experiments (n = 4). CFU potential of progenitors similarly sorted from cord blood (CD45/CD43+CD34+) is shown in red.
(B) Lymphoid/myeloid differentiation assay performed on iPSC-derived hematopoietic cells. FACS plots and bar graphs showing non-
myeloid (CD33/CD14-), CD19-, CD56+, and CD56+CD16+ NK fraction from wells seeded with 50 HSC-like cells (CD45/43+CD34hi
CD38loCD90+CD45RA-) (17 individual wells) cultured on OP9 stroma for 4 weeks. Left bar graph shows the cluster size of the NK fraction.
Right bar graph shows the frequency of this population in the viable non-stroma fraction. See also Figure S2.
(C) FACS plots showing non-myeloid, CD7+, CD45RA+ multipotent early lymphoid progenitors from 3,500 sorted CD34+ cells cultured on
OP9DL1 stroma for 3 weeks from one out of two independent experiments (n = 2). FACS plots are gated on the viable non-stroma fraction.
Bar graph show the total output of differentiated cells from progenitors generated with DMSO, DEAB, or RA. FACS gates are based on FMO
controls.
Data represent mean ± SEM. Asterisks indicate significant differences (*p < 0.05).
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CD34 and CD90, while being negative for blood markers
CD45 and CD43 (Kennedy et al., 2012; Timmermans
et al., 2009), we observed that the frequency of these cells
were significantly decreased when RA had been added to
the culture, on the other hand, DEAB enhanced the propor-
tion of such precursors (Figures 4B and S3). While these
findings demonstrate that part of the improvements seen
with decreased RA signaling on blood generation efficiency
is developmentally mediated, it does not identify at what
stage in the developmental process that this takes place.
To evaluate this, we performed quantitative gene expres-
sion analysis for a range of developmental marker genes
at multiple defined time points throughout our differenti-
ation protocol. The genes and primers used are detailed
in Table S1. By this approach, we identified two separate
developmental time points where reduced RA signaling
would be important for correct lineage commitment to-
ward final hematopoietic mesoderm. The first time point
identified was at day 4 during initial germ layer commit-
ment, where mesoderm, measured by expression of BRA-
CHYURY, were decreased by RA and increased by DEAB
(Figures 4C and 4D). The second time point identified
was at day 8 during the later posterior/anterior specifica-
tion of the lateral plate mesoderm (LPM), where posterior
LPM is the precursor of hemangiogenic mesoderm and
the anterior LPM is the precursor of cardiogenicmesoderm.
At this time point, we observed a decrease in cardiogenic
mesodermal marker gene NKX2.5 expression in samples
treated with DEAB, indicating that decreased RA signaling
can decrease the commitment toward cardiogenic lineage
(Figures 4C and 4D). In agreement with this, we observed
a significant decrease in the frequency of spontaneously
contracting embryoid bodies later at day 15 in our cultures
(Figure 4E), strongly indicating that low levels of RA
signaling reduce the commitment of differentiating meso-
derm toward the non-hematopoietic cardiac lineage. In
addition we observed upregulated expression of CD38 in
cultures with RA, suggesting a possible differentiation of
hematopoietic progenitors into more mature CD38+ cells
(Figures 1C and 4D). These findings demonstrate that the
positive effects of RA signaling inhibition on the efficiency
of hematopoietic progenitors generated from pluripotent
stem cells is through the mechanism of increased develop-
mental commitment toward the hematopoietic lineage.
Retinoic Acid Signaling Inhibition Maintains
the More Primitive Phenotype of Generated
Hematopoietic Progenitors
Modulation of RA signaling has earlier been described
to affect the maintenance and expansion (Chute et al.,
2006; Muramoto et al., 2010; Purton et al., 2000, 2006) of
subcultured hematopoietic progenitors in the adult setting.
We evaluated if there was any beneficial effect of reducedStem CellRA signaling on the generated hematopoietic fraction dur-
ing an additional extended culture period. We observed
that the early hematopoietic population, present at day
16, to a large extent is composed of progenitors with a
more immature phenotype (CD38CD90+), while pro-
longed cultures until day 21 display a maturational shift
where the more mature cell fraction (CD34CD38+) be-
comes expanded (Figure 5A), thus indicating a relationship
between the hematopoietic fractions similar to the current
models of lineage determination in the adult hematopoiet-
ic hierarchy (Doulatov et al., 2012). We then analyzed the
relative distribution of the progenitor fraction and HSC-
like fraction within the hematopoietic population at days
16 and 21 with or without DEAB treatment. While the
DMSO control demonstrated the typical loss of progenitors
(CD34+) with increased amounts of more mature cells
(CD34CD38+) (Figure 5B, left and middle panel), DEAB
reduced this transition. Furthermore, the increase in HSC-
like frequency was increased for cultures with DEAB that
were kept until day 21, relative to 16 days (Figure 5B, right
panel). These findings indicate that reduced RA signaling
better maintains the immaturity of the generated hemato-
poietic progenitor fraction. Taken together, these results
demonstrate that RA signaling influences the development
of blood through the two mechanisms of developmental
commitment and blood progenitor maturation and that
decreased RA signaling enables increased generation effi-
ciency of hematopoietic progenitors from human pluripo-
tent stem cells in vitro.DISCUSSION
In this study, we dissected the role of RA signaling in hu-
man hematopoietic development, using a human pluripo-
tent stem cell differentiation system as an in vitromodel, to
generate hematopoietic progenitors. We have identified
multiple stages in development that are influenced by RA
signaling, where modulation of RA signaling directs the
generation of hematopoietic cells from pluripotent stem
cells in vitro. We report that RA decreases blood generation
from human pluripotent stem cells. RA signaling inhibi-
tion before the onset of hematopoiesis establishes an in-
crease in the final output of cells with an HSC-like pheno-
type that confirms the role of RA signaling in the early
stages of blood generation. qRT-PCR analysis for genes
marking specific developmental cell types identified the
stages during development where decreased RA signaling
increased commitment toward the hematopoietic lineage,
including the initial commitment of pluripotent stem
cells to mesoderm, and by increased specification toward
hemangiogenic mesoderm, while reducing cardiac meso-
derm differentiation. The suppressing effect of RA onReports j Vol. 4 j 269–281 j February 10, 2015 j ª2015 The Authors 275
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Figure 4. Decreased Retinoic Acid Signaling Improves Early Developmental Commitment toward the Hematopoietic Lineage
(A) Frequency of the HSC-like fraction in cultures supplemented with DEAB (10 mM), during the first 8 days (n = 3) or during the full 16 days
of differentiation (n = 7), as compared to DMSO control. Experiments are independent biological replicates.
(B) Frequency of the CD43CD34hiCD90hi mesoendothelial precursors of the hematopoietic lineage at day 8 for cultures treated with DEAB
or RA (n = 4). See also Figure S3.
(legend continued on next page)
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AB
Figure 5. Decreased Retinoic Acid Signaling Maintains the Primitiveness of Generated Hematopoietic Progenitors
(A) Representative FACS profiles of cells harvested at day 16 and after extended culture period at day 21. Cells were treated with or without
DEAB at 10 mM during the whole culture period.
(B) Graphs showing fold changes in maturation of the hematopoietic population (CD45/43+) observed between day 16 and day 21 for cells
treated with DEAB or DMSO from three independent experiments (n = 3).
Data represent mean ± SEM. Asterisks indicate significant differences (*p < 0.05).mesodermal commitment has been described in the mu-
rine embryo (Bain et al., 1996; Okada et al., 2004), and
RA has been demonstrated to direct mesoderm toward car-
diac tissue (anterior LPM) at the expense of hematopoietic
development in Xenopus (Deimling and Drysdale, 2009),
zebrafish (de Jong et al., 2010), and mouse (Szatmari
et al., 2010), but this is the first time that these functions
of RA have been verified in human development. Taken(C) Lineage map of the developmental process from pluripotent stem c
without DEAB were analyzed at days 4, 8, 12, and 16 during differen
(mesoderm), MIXL1 (mesoderm), SOX17 (endoderm), SOX1 (ectoderm
(D) Expression of developmental marker genes BRACHYURY, NKX2.5,
compared to DMSO control.
(E) Frequency (%) of beating colonies at day 15 during differentiatio
Data represent mean ± SEM. Asterisks indicate significant differences
Stem Celltogether, these results suggest that high but physiological
levels of RA antagonize blood development and that sub-
stantially lower amounts of RA signaling relative to other
tissues in the developing embryo are required to facilitate
blood development. We show that RA accelerates the dif-
ferentiation of generated hematopoietic progenitors to
more mature blood cells, in agreement with findings in
the adult human bone marrow where RA scavengingell to hematopoietic cell. Adjacent wells of cultures treated with or
tiation by qRT-PCR for developmental genes including BRACHYURY
), and NKX2.5 (cardiac mesoderm).
and CD38 for cultures treated with DEAB (n = 3) or RA (n = 2) as
n in the presence of DEAB compared to DMSO control (n = 2).
(*p < 0.05, ****p < 0.0001).
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stroma cells is crucial to prevent rapid differentiation of he-
matopoietic progenitors (Ghiaur et al., 2013). By restricting
RA signaling using DEAB, we demonstrate a significant in-
crease in the generation of HSC-like progenitors capable of
lymphoid and myeloid differentiation (3-fold). In this
study, we performed transplantation experiments to assess
the capacity of these cells to repopulate immunocompro-
mised mice but found no significant difference in engraft-
ment capacity in progenitors derived from human pluripo-
tent stem cells (data not shown). Our results using DEAB
may appear to contradict findings that RA can increase
the progenitor output generated from human ESCs (Yu
et al., 2010); however, Yu et al. only assessed the effect of
RA on the general CD34+ progenitors and did not address
the action of RA to differentiate and ultimately reduce
the numbers of more immature hematopoietic progeni-
tors; indeed, we observed that adding low amounts of RA
increased total blood output but at the expense of the
HSC-like progenitor fraction (the fraction with the highest
lymphoid/myeloid differentiation potential). Our findings
indicate that reduced RA signaling preserves the generated
progenitor fraction from differentiation into more mature
cell types, similar to the finding that DEAB delayed the dif-
ferentiation of subcultured human cord blood and bone
marrow HSCs (Chute et al., 2006). Regarding the role of
RA signaling on blood development, a recent study on
the cephalochordate Amphioxus (Branchiostoma lanceola-
tum), considered to be one of themost closely related inver-
tebrates to the vertebrate family (Pascual-Anaya et al.,
2013), reported that HSC-equivalent Pdvegfr+ Scl+ cells in
the aorta-gonad-mesonephros (AGM) during embryonic
development were abrogated when the embryos were
treated with RA. This indicates that first, RA, at concentra-
tions above what is naturally found at embryonic sites of
hematopoiesis, can be a strong negative regulator of blood
development, and second, that the relationship between
RA signaling and development toward the hematopoietic
lineage is a shared feature across all members of the verte-
brate subphylum. Therefore, it is possible that, from an
evolutionary perspective, blood development depends on
an RA-low environment with controlled low levels of RA
being critical during separate stages during this process, a
process mimicked in our human model in the presence of
DEAB.While our data demonstrate that increasing concen-
trations of RA abrogate the development of blood, it is
important to appreciate that RA signaling is needed in
this developmental process, albeit at controlled levels,
since full abrogation of RA signaling, as demonstrated in
the murine setting (Chanda et al., 2013; Goldie et al.,
2008), is incompatible with hematopoietic development
and the emergence of HSCs at the AGM. In addition,
Chanda et al. demonstrate that increases in RA signaling
around the time of HSC emergence from hemogenic endo-278 Stem Cell Reports j Vol. 4 j 269–281 j February 10, 2015 j ª2015 The Athelium increase transplantable HSCs in the murine
setting; however, whether any expansion of already-com-
mitted HSCs occurred in the culture was not addressed.
Our concept that RA is required at low levels during blood
development helps to explain the contradicting views on
RA in blood development and provides a more unified
model for this process. As RA has been shown to have pleio-
tropic effects on separate hematopoietic cell types (Purton,
2007), and by the evidence that signaling through specific
receptor elements confers separate responses in different
populations (Chanda et al., 2013; Purton et al., 2006), it
would be fitting to describe the nature of RA signaling to
be context dependent. Identification and manipulation
of specific RA receptors in specific cell populations will
allow for further understanding and better recapitulation
of development toward blood. Taken together, we have
provided evidence identifying multiple developmental
stages that depend on restricted RA signaling for the effi-
cient differentiation toward blood, and we have shown
that RA signaling inhibition can prevent differentiation
and loss of more immature blood progenitors generated
in vitro. Our findings show the utility of our pluripotent
stem cell differentiation system to study human hemato-
poietic development, modeling human embryonic devel-
opment, and to determine the effects and functions of RA
during this process.EXPERIMENTAL PROCEDURES
Pluripotent Stem Cell Culture and Hematopoietic
Differentiation
The human ESC lines H1 and HUES 3 (obtained from WiCell and
Harvard University, respectively, under material transfer agree-
ments) and the iPSC cell line RB9-CB1 (derived from cord blood
endothelial cells transduced with tetracycline-inducible lentiviral
vectors expressingOCT4, SOX2, LIN28, KLF4, and C-MYC) (Woods
et al., 2011) were used in this study. The lines were karyotypically
normal and have previously been demonstrated to be pluripotent
by in vivo teratoma assay and PCR. The pluripotent stem cell lines
were routinelymaintained and differentiated toward blood, as pre-
viously described (Woods et al., 2011), with some modifications.
Themodificationswere as follows: prior to embryoid body (EB) for-
mation, colonies of pluripotent stem cells were cultured an addi-
tional 24 hr to increase colony density. During the EB-formation
stage, the 7-day culture was extended to 8 days with a 1.5-fold in-
crease in media volume. For adherence plating of EBs, a coating
of Matrigel was used instead of OP9 stroma. The pluripotent
stem-cell-to-blood differentiation mediumMesoTotal (Primorigen
Biosciences), with andwithout DEAB, was added 24 hr after EB for-
mation, and fresh media was added every 2 days throughout the
differentiation until day 16 or day 21 (extended culture period).
DEAB (Sigma), LG1506 (Tocris Bioscience), and RA (Sigma)were re-
suspended in DMSO and added at specific concentrations to the
differentiation media.uthors
Flow Cytometry
Differentiated cells werewashed inPBSbefore being singularizedus-
ing TrypLE (Thermo Fischer Scientific), passed through a 21G nee-
dle, and filtered using 30 mm sterile Cup Filcons (BD Biosciences).
Cells were treated with 7AAD to exclude dead cells. Cells were
stained using the following anti-human antibodies; fluorescein iso-
thiocyanate (FITC)-conjugated CD45 (eBioscience, 11-0459-42)
and CD43 (BD Biosciences, 555475), phycoerythrin-cyanine (PE-
Cy7)-conjugated CD34 (BioLegend, 343516), allophycocyanin-
conjugated CD38 (BioLegend, 303510), CD33 (BioLegend,
303408), CD14 (BioLegend, 325608) Phycoerythrin (PE)-conju-
gated CD90 (BioLegend, 328110), CD19 (BioLegend, 302208),
CD7 (BD Biosciences, 332774), V450-conjugated CD45RA (BD Bio-
sciences, 560362), PE-Cy5-CD56 (BioLegend, 304608), BV605-
CD45RA (BioLegend, 304133), and eFluor450-CD16 (eBioscience,
48-0168-42). Cells were acquired on a FACS Canto II (BD Biosci-
ences) or sorted using a FACS Aria III (BD Biosciences). Analysis
was done using FlowJo, version 9.4.10 (BD Biosciences). FACS gates
are based on fluorescence minus one (FMO) controls unless stated
otherwise.
CFU Assay
Single-cell suspensions of harvested differentiation cultures
(20,000 cells per well) or, alternatively, sorted blood progenitor
cells were plated in 2ml ofMethoCult H4435 (STEMCELLTechnol-
ogies) in Falcon Tissue Culture six-well plates (Thermo Fisher Sci-
entific). RA and DEABwere not added to themethylcellulose. Cells
were incubated for 14 days in a humidified incubator at 37C with
5% CO2. Colonies were counted by bright-field microscopy.
Lymphoid Differentiation Assay
EBs obtained frompluripotent stemcells were differentiated onOP9
(Martin et al., 2008) andOP9-Delta1 (OP9D1) (Kennedy et al., 2012)
stromamonolayer forNK cell and Tcell differentiation, respectively,
in Dulbecco’s modified Eagle’s medium supplemented with 20%
fetal bovine serum. To obtain NK cells, EBs were differentiated for
4 weeks in the presence of interleukin-3 (IL-3) (5 ng/ml), IL-7
(5 ng/ml), stem cell factor (SCF) (10 ng/ml), and Flt-3L (10 ng/ml)
(all from PeproTech). Wells were scored positive if showing a cluster
of more than ten NK cells. To obtain T cells, CD34+ hematopoietic
progenitors obtained from the differentiating EBs were plated on
OP9D1 cells and differentiated for 3 weeks in the presence of Flt-
3L (5 ng/ml) and IL-7 (5 ng/ml). SCF (100 ng/ml) was applied
only for the initial 5 days. The differentiating cells were collected
(vigorous pipetting and filtering through a 40 mm nylon mesh)
and re-plated every 7 days on fresh stroma. Fresh media and cyto-
kines were replenished twice every 7 days. At the end of subculture,
cells were collected and analyzed by flow cytometry. Cord blood
cells, collected after informed consent at the LundUniversity hospi-
tal, were used as positive control and were prepared using Lympho-
prep tubes (Axis-Shield), togetherwithCD34+ enrichment using the
Direct CD34 Progenitor Cell Isolation Kit together with MACS sep-
aration columns (both from Miltenyi Biotech).
Quantitative Real-Time PCR
RNA was extracted from differentiation cultures with the RNeasy
Micro Kit (QIAGEN) according to the manufacturer’s specifica-Stem Celltions. The extracted RNAwas transcribed into cDNA using random
hexamers, dinucleotide triphosphates (dNTPs), 53 first strand
buffer, DTT, RNaseOUT, and SSIII (Thermo Scientific). The qRT-
PCR analysis was carried out with SYBR green (Sigma) detection us-
ing Platinum Taq polymerase, SYBR green, and Rox reference dye,
dNTPs (all from Thermo Scientific), and primers (Sigma) (for
primer sequences, see Table S1) on an ABI 7900HT Fast Real Time
PCR cycler (Thermo Scientific). Reaction efficiency was calculated
for each primer pair with serial dilutions of cDNA template, and
melting curve analysis was performed at the end of each reaction
for detection of unspecific product amplification. Relative quanti-
fication of transcript levels were calculated using DCT values
normalized to b-ACTIN, and the fold change of gene expression
was calculated relative to day 0 of differentiation.
Statistical Analysis
Statistical analysiswas performedusing anunpaired Student’s t test,
and the results were considered to be statistically significant at p
value < 0.05. All graphs depict mean ± SEM. The number of biolog-
ical replicates is indicated by the n value. The graphs and statistical
evaluation were done using GraphPad Prism (GraphPad Software).
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